Trial Profile
Prospective Study of Predictive Factors of Sustained Remission of Crohn's Disease After Stopping Infliximab.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 29 Sep 2015
Price :
$35
*
At a glance
- Drugs Infliximab (Primary)
- Indications Crohn's disease
- Focus Therapeutic Use
- Acronyms STORI
- 22 Jul 2010 Actual end date (Jul 2010) added as reported by ClinicalTrials.gov.
- 22 Jul 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 11 Oct 2009 New trial record